New J&J CEO Gorsky wants to grow device business | Wall Street Beat Wall Street Beat

When Alex Gorsky takes the helm at Johnson & Johnson (NYSE:JNJ) tomorrow, he’ll become responsible for a company bedeviled by a series of high-profile, big-ticket recalls, a more than $1 billion legal settlement – and blessed with the world’s largest medical device business.

In his first public comments ahead of replacing Bill Weldon as CEO, Gorsky told Bloomberg that he plans to make that business even bigger, using some of the $14 billion in cash at his disposal to expand J&J’s footprint in med-tech.

Sign up to get our free newsletters delivered straight to your inbox

Saying there’s value in being a diversified conglomerate, Gorsky told the news service that he has no plans to emulate rival Abbott (NYSE:ABT), which is in the process of carving out its research pharmaceuticals business into a separate firm called AbbVie. The focus at J&J under his watch will be on growth, especially in emerging markets like China, he said.

"We are committed to being diversified across the whole health-care continuum," Gorsky said. "When there are large opportunities that we think can give us some strategic advantage, we will obviously take a look."

As for those recalls, including the shelving of J&J’s DePuy ASR hip implant – which is shaping up to be the most expensive recall ever, with about 6,000 lawsuits filed so far – the new CEO said he’ll work to get the recalled metal-on-metal hip devices and over-the-counter drugs back on the market as soon as possible. Changes are already afoot to address the problems, he said, but declined to go into detail, according to Bloomberg.

"We realize we have a lot of work to do, but the most important thing we think we can do is get the products back on the shelf," Gorsky said. "We know we are going to have to win the hearts and minds and pocketbooks of the consumer."

"I don’t think the company is so broken that it needs to be completely repaired," Thrivant Financial for Lutherans portfolio manager David Heupel told the news service. "A lot of the elements you need for improvement are there. It’s just an execution issue."

 Fitch holds steady on J&J’s long-term debt
Fitch Ratings affirmed J&J’s long-term "AAA" debt ratings and removed its "Negative Rating Watch." Read more

 Accuray deepens its stake in Compact Particle Acceleration
Accuray (NSDQ:ARAY) said it added to its stake in a development-stage company it bought into when it acquired rival TomoTherapy last year for $277 million.

Established in 2008 by TomoTherapy, Compact Particle Acceleration Corp. is working on a compact proton therapy system for cancer. Accuray said it dropped $1.1 million in cash on CPAC April 20 in return for equity and warrants. Including the conversion of a bridge loan worth about $1.3 million, Accuray now owns about 16.3% of CPAC and could further boost that stake to 19%.
Read more

 Arrhythmia Research gets de-listing notice
Arrhythmia Research Technology (NYSE:HRT) said the New York Stock Exchange’s AMEX exchange warned of a possible de-listing due to its failure to file an annual report on time. The exchange gave the company until May 1 to submit a compliance plan, but Arrhythmia Research might have gotten off the hook today, when it released its 2011 earnings report. 
Read more

 CorMedix does too

Arrhythmia Research wasn’t the only publicly traded device maker to run afoul of is exchange’s rules. CorMedix (NYSE:CRMD)
said the NYSE’s Amex market warned it could get the boot, too, unless it submits a compliance plan by May 21 to rectify "losses in 2 of its most recent fiscal years with equity below $2 million."
Read more

 Gabelli slashes stake in Zoll
Über-investor Mario Gabelli, who boosted his stake in Zoll Medical (NSDQ:ZOLL), shortly after it received a $2.21 billion cash offer from Asahi Kasei Corp. (TYO:3407), slashed his holdings in the AED maker from 6.7% to less than 1%.
Read more

 Funding Roundup

 Analysts’ ups and downs

  • 3M Co. (NYSE:MMM): UBS raises estimates, boosts price target to $100, maintains "buy" rating; Goldman Sachs increases price target from $87 to $90, maintains "sell" rating; Jefferies & Co. increases price target from $102 to $108, maintains "buy" rating.
  • C.R. Bard (NYSE:BCR): Leerink Swann maintains "market perform" rating.
  • Cynosure (NSDQ:CYNO): Needham & Co. re-affirms "buy" rating.
  • Edwards Lifesciences (NYSE:EW): Canaccord Genuity reinforces "buy" rating, $86 price target.
  • Integra LifeSciences (NSDQ:IART): Bank of America raises price target from $26 to $36.
  • Intuitive Surgical (NSDQ:ISRG): Zacks Equity Research upgrades to "outperform," sets $701 price target; Raymond James upgrades to "outperform."

RSS From Medical Design & Outsourcing

  • Molex delivers ISO 13485-compliant, medical-grade surgical cables from its class 100,000 clean room facility
    Molex, LLC operates a fully ISO 146441-1:1999 Class 8-certified clean room, satisfying strict particulate contamination levels specified by ISO-compliant requirements. Located in Thailand, the facility has less than 100,000 particulates (≥0.5µm) per cubic foot of air and manufactures a variety of ISO 13485-compliant medical cables and surgical cables used in operating theatres, hospitals, laboratories and […]
  • Swept-Source OCT: Patent license agreement between Massachusetts General Hospital and Heidelberg Engineering
    Heidelberg Engineering has entered into a patent license agreement with Massachusetts General Hospital (MGH) in Boston. The agreement grants global and exclusive rights to 77 basic patents and patent applications which relate to swept-source OCT technology and its application in ophthalmology. Spectral domain OCT has become indispensable to eye care professionals worldwide to diagnose and […]
  • MIT’s MultiFab presents a stark challenge to incumbent 3D Printer manufacturers’ hardware, software, and business Models
    MIT’s Computational Fabrication Group recently announced the MultiFab, a low-cost 3D printer that can combine up to 10 different resins in one part and also includes a 3D scanning system to identify and fix errors during production. According to Lux Research, these capabilities are rare in commercial 3D printers today due to the manufacturers’ need […]
  • AVX releases Accu-P MP medical grade film chip capacitors for medical devices
    AVX Corporation, a leading manufacturer of passive components and interconnect solutions, has released a new series of thin film chip capacitors specifically designed to meet the demanding performance specifications for implantable medical devices. Delivering extremely tight capacitive tolerances, exceptionally repeatable performance, and remarkably low ESR and high Q at high frequencies—including VHF, UHF, and RF […]
  • RIVANNA commences manufacturing of its Accuro device
    Rivanna Medical announced that it has begun manufacturing its FDA-cleared Accuro device, a handheld and untethered smart-phone-sized device that is designed to guide spinal anesthesia with automated 3D navigation technology in addition to ultrasound imaging of abdominal, musculoskeletal, cardiac and peripheral vascular anatomies. The product will be launched at the ASA annual meeting in San […]
  • FDA seeks public input on Quality Metrics guidance
    by Oliver Wolf, Senior Product Manager, MasterControl In line with the general shift towards risk-driven approaches in the quality management world, FDA is now taking steps towards applying those same principles to its own auditing schedule. At the end of July, the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation […]
  • First ‘Ear Wear’ for Active Adults Debuts with MDHearingAid FIT
    If you’ve burned out your ears with earbuds, headphones or decades of other audio abuse but aren’t ready for your grandmother’s hearing aids, not to worry! The new MDHearingAid FIT gets you back in the game with a tiny, FDA-registered, one-size-fits-most solution that doesn’t block your ear canal like old-fashioned in-the-ear hearing aids. The FIT feels […]
  • CardioGenics enters into manufacturing agreement with Ontario-based Plasticap
    CardioGenics Holdings, developer for the In-Vitro-Diagnostics (“IVD”) testing market, announced that it has entered into a manufacturing agreement with Plasticap of Ontario, Canada, pursuant to which Plasticap will manufacture CardioGenics’ proprietary self-metering cartridges for its QL Care analyzer. The term of the agreement is three years and the purchase price for each cartridge shall be […]
  • MTD Micro Molding releases micro materials menu
    MTD Micro Molding, a long-time leader in micro-injection molding, has released an updated “Materials Menu” of materials that can be successfully micromolded to help guide engineers at medical device companies. Material selection is a crucial step in product manufacturability. The correct material drives tolerance, dimension, strength, usabality, speed-to-market, design, critical features, and cost. Through MTD’s […]
  • MedTech Chat: Elastic technology for drug delivery
    Dr. Zhen Gu and Dr. Yong Zhu from North Carolina State University are both co-senior authors of a research paper describing their recent work. Dr. Gu, Dr. Zhu and other researchers from North Carolina State University and the University of North Carolina at Chapel Hill have developed a drug delivery technology that consists of an […]
  • B. Braun’s OEM Division offers large bore normally closed low-pressure check valves
    Infusion therapy and pain management device manufacturer B. Braun said today it is offering normally closed large-bore low-pressure check valves through its valve-focused contract manufacturing OEM division. The valves, offered by Bethlehem, Pa.-based B. Braun, are designed for the intermittent injection of fluids during medical treatment and open automatically when pressure is applied. The newly […]

Leave a Reply